Deep roots grow success.

Our leadership team brings their passion and expertise to work every day—and it shows in our ability to bring products from clinical trial to patients, with exceptional speed.

We’re focused on aggressive portfolio growth, and our team brings the requisite experience, including:

Sean Brynjelsen

Chief Executive Officer & Director

With more than 20 years in the pharmaceutical industry, Sean has developed extraordinary business acumen and particular expertise in business and product development.

More

Notable Experience

  • Executive Vice President, Business Development at Sagent Pharmaceuticals, a generic injectable company acquired by Nichi-Iko Pharmaceutical Co.
  • Senior Vice President, Global Business Development at Akorn, Inc., a pharmaceutical company specializing in ophthalmic and injectable products
  • Product development, injectable pharmaceuticals at Baxter, Abbott, and Hospira

Education

  • MBA, University of Notre Dame
  • MS, Chemistry, University of Illinois
  • BS, Chemistry, University of Illinois

Wilson Troutman, CPA

Chief Financial Officer

Throughout Wilson’s more than 30 years of experience in finance and accounting, he has successfully led departments in both start-ups and public companies.

More

Notable Experience

  • Chief Financial Officer at Omeda Communications, a private data-analytics and data storage company
  • Corporate Controller and Treasurer at Akorn, Inc., where he was responsible for Sarbanes- Oxley Act implementation, SEC reporting, and cash management

Education

  • MBA, University of Chicago
  • BS, Accounting, University of Illinois—Urbana

Bharathi Devarakonda, PhD

Senior Vice President, Regulatory Affairs & Technical Services

Bharathi oversees the development and regulatory activities for all of our products, bringing her significant experience in pharmaceutical product development and regulatory submissions to bear daily.

More

Notable Experience

  • Product development and regulatory affairs at Morton Grove Pharmaceuticals (acquired by Wockhardt); Akorn, Inc.; Hospira (acquired by Pfizer); Rockwell Medical, Inc.; Medefil, Inc.
  • Filed more than 80 original NDA, ANDA, and ANADA applications with the FDA
  • Significant academic research experience in formulation development and drug delivery

Education

  • PhD, Pharmaceutics, University of Louisiana— Monroe
  • MS, Pharmaceutics, Indian Institute of Technology (Banaras Hindu University)
  • BS, Pharmacy, Andhra University
  • MBA, Lake Forest Graduate School of Management

Ingrid Hoos

Senior Vice President, Regulatory Affairs

Ingrid is responsible for regulatory and medical affairs activities, applying nearly 4 decades of experience in global biomedical and pharmaceutical product development—and with regulatory agencies in the US, Europe, Canada, and Japan.

More

Notable Experience

  • Vice President, Regulatory affairs at Horizon Therapeutics
  • Regulatory affairs consultant at Vantage Consulting International, Inc.
  • Regulatory affairs at Takeda Pharmaceutical; Searle; Baxter Healthcare

Education

  • BS, Chemistry, Northeastern Illinois University
  • BS, Biology, Northeastern Illinois University

Paul Stickler

Senior Vice President, Commercial

Paul has spent more than half of his
3 decades in the pharmaceutical industry developing a specialty in the rare disease space of inborn error of metabolism, endocrinology, neurology, and neonatology.

More

Notable Experience

  • Vice President, Commercial Operations at Recordati Rare Diseases, where he developed the commercial footprint, including the strategic and operational goals and the field force and marketing support
  • Vice President and General Manager, Hospital and Mature Business, Lundbeck/Ovation Pharmaceuticals
  • Vice President, Sales for Lundbeck’s rare disease/ specialty salesforce
  • Sales and marketing training, management, and regional and national leadership at Abbott Laboratories (now AbbVie)

Education

  • BA, Political Science, Purdue University

David Krempa

Senior Vice President, Business Development & Investor Relations

David is responsible for our business development, corporate strategy, and investor relations activities.

More

Notable Experience

  • Business development, Sagent Pharmaceuticals; Akorn, Inc.
  • Equity analyst at Morningstar, Inc., covering the specialty pharmaceutical industry
  • Chartered Financial Analyst (CFA)

Education

  • BS, Finance, DePaul University

Scott Grossenbach

Vice President, Sales Operations

Scott is responsible for the commercialization of our products, applying more than 20 years of experience in pharmaceutical sales and marketing, commercial operations, and supply chain.

More

Notable Experience

  • Executive Director, Sales at Akorn, Inc.
  • General Manager, SubTerra, a division of CanniMed Therapeutics

Education

  • MBA, University of Michigan
  • BS, Engineering, Michigan Technological University

Danka Radosavljevic

Vice President, Quality

Danka is responsible for implementation and oversight of Quality GxP Systems encompassing product development, manufacturing, analysis, and distribution to maintain compliance with regulatory requirements and ensure patient safety.

More
Notable Experience

  • Analytical Scientist/Project Manager at Akorn, Inc.
  • Quality Control/ Analytical Development Scientist at Morton Grove Pharmaceuticals

Education

  • BS, Earth and Environmental Science (Geochemistry), University of Illinois at Chicago

Intrigued?

Learn about the accomplished executives who comprise our board.